TWD 44.5
(0.0%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 582.93 Million TWD | 996.84% |
2022 | -34.14 Million TWD | -148.52% |
2021 | 133.32 Million TWD | -72.29% |
2020 | 493.8 Million TWD | -0.62% |
2019 | 484.03 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | 61.37 Million TWD | 163.07% |
2024 Q1 | 35.05 Million TWD | -95.66% |
2023 Q4 | 524.96 Million TWD | 865.93% |
2023 FY | - TWD | 996.84% |
2023 Q3 | 54.34 Million TWD | 140.84% |
2023 Q2 | -133.08 Million TWD | -199.51% |
2023 Q1 | 133.73 Million TWD | 325.74% |
2022 Q4 | -59.24 Million TWD | 0.0% |
2022 FY | - TWD | -148.52% |
2021 FY | - TWD | -72.29% |
2020 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Allied Biotech Corporation | 204.79 Million TWD | -184.648% |
GeneFerm Biotechnology Co., Ltd. | 231.09 Million TWD | -152.251% |
Easywell Biomedicals, Inc. | -85.5 Million TWD | 781.79% |
TTY Biopharm Company Limited | 1.52 Billion TWD | 61.759% |
Synmosa Biopharma Corporation | 1 Billion TWD | 42.211% |
Center Laboratories, Inc. | -175.17 Million TWD | 432.784% |
Tien Liang BioTech Co., Ltd. | 31.04 Million TWD | -1777.535% |
Orient Pharma Co., Ltd. | 172.39 Million TWD | -238.14% |
InnoPharmax Inc. | -62.12 Million TWD | 1038.405% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 126.67 Million TWD | -360.172% |
Excelsior Biopharma Inc. | -29.36 Million TWD | 2084.872% |
DV Biomed Co., Ltd. | 407.64 Million TWD | -43.003% |
Foresee Pharmaceuticals Co., Ltd. | -912.16 Million TWD | 163.907% |
Handa Pharmaceuticals, Inc. | 802.78 Million TWD | 27.386% |
UniPharma Co., Ltd. | -16.25 Million TWD | 3686.422% |
Anxo Pharmaceutical Co., Ltd. | 131.31 Million TWD | -343.94% |
Alar Pharmaceuticals Inc. | 394.52 Million TWD | -47.759% |
Winston Medical Supply Co., Ltd. | 228.32 Million TWD | -155.31% |
Mercury Biopharmaceutical Corporation | -39.03 Million TWD | 1593.408% |
Bioray Biotech Co., Ltd | 12.13 Million TWD | -4703.766% |
TSH Biopharm Corporation Limited | 99.35 Million TWD | -486.751% |